Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs
Crossref DOI link: https://doi.org/10.1007/s10067-016-3332-8
Published Online: 2016-06-22
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bhati, Manjeet
Bandyopadhyay, Syamasis
License valid from 2016-06-22